Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Egrifta (Tesamorelin Acetate) Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
Historical growth was primarily driven by a surge in hiv-associated lipodystrophy cases, adverse effects stemming from prolonged antiretroviral therapy, the clinical affirmation of ghrh analogs, a heightened understanding of the dangers associated with visceral fat, and an ongoing demand for specific abdominal fat reduction solutions.
Future growth during the forecast period is projected to stem from the advancements in personalized HIV care, the expansion of the pipeline for peptide therapeutics, a rise in the diagnosis of metabolic complications, favorable reimbursement policies for specialty drugs, and a concentrated effort on enhancing the long-term quality of life for HIV patients. Prominent trends anticipated in this period feature the emergence of long-acting peptide therapies, individualized lipodystrophy treatment approaches, an expansion of indications for metabolic conditions, patient-focused injectable therapies, and an increased adoption of specialty biologic drugs.
Get A Free Sample Report With In-Depth Market Insights:
Egrifta (Tesamorelin Acetate) Market Growth Momentum: What Factors Are Shaping Demand?
The growing incidence of human immunodeficiency virus (HIV) cases is a significant catalyst for the future expansion of the egrifta (tesamorelin acetate) market. Human immunodeficiency virus (HIV) cases denote situations where individuals have contracted HIV, leading to a gradual weakening of their immune system. This escalation in HIV is partly attributable to inadequate public knowledge and education concerning preventive strategies, such as the consistent use of condoms and routine testing, particularly within demographics at higher risk. Egrifta works by encouraging the release of growth hormone, which aids in reducing surplus visceral fat and refining body composition, ultimately elevating the holistic health and life quality for those affected by HIV. For example, in May 2024, the Minnesota Department of Health, a US-based state health agency, reported 324 new HIV diagnoses in 2023, indicating a 24% rise from 2022. Therefore, the rising occurrence of human immunodeficiency virus (HIV) cases is propelling the growth of the egrifta (tesamorelin acetate) market.
Egrifta (Tesamorelin Acetate) Market Segment Analysis Spotlighting Growth Areas
The egrifta (tesamorelin acetate) market covered in this report is segmented –
1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) By End-Users: Hospitals, Specialized Clinics, Home Care
Egrifta (Tesamorelin Acetate) Market Trends Redefining Industry Growth
A significant trend within the egrifta (tesamorelin acetate) market is the dedication to developing sophisticated synthetic peptide drugs to enhance the effectiveness of treatments for HIV-related lipodystrophy. Synthetic peptide drugs are compounds meticulously designed to deliver specific therapeutic effects by mirroring or boosting the actions of naturally occurring peptides. For instance, in December 2024, Theratechnologies Inc., a Canada-based biopharmaceutical company, announced the resumption of EGRIFTA SV production following a voluntary halt at its contract manufacturer’s facility due to observations from an FDA inspection. A recently manufactured batch has completed quality control checks and will be released once the US Food and Drug Administration (FDA) approves a prior approval supplement; concurrently, two additional batches are currently in production. The company is actively managing its inventory to fulfill patient demand until mid-January 2025 and is collaborating with the FDA to prevent a shortage in 2025. EGRIFTA SV is exclusively distributed within the United States.
Egrifta (Tesamorelin Acetate) Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.
View The Full Egrifta (Tesamorelin Acetate) Market Report:
Egrifta (Tesamorelin Acetate) Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
